Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis C
  Free Subscription

Articles published in
Hepatology
    March 2026
  1. RAHMAN SA, Gangadhara S, Gridley J, Mala U, et al
    T and B cell targeting DNA/MVA HCV vaccines induce strong and broad cellular and humoral immunity in mice and rhesus macaques.
    Hepatology. 2026 Mar 6. doi: 10.1097/HEP.0000000000001732.
    >> Share

    January 2026
  2. GOMEZ-ESCOBAR E, Flores N, Shoukry NH
    Erratum: One step closer to a pan-genotypic hepatitis C vaccine.
    Hepatology. 2026;83:E72.
    >> Share

    November 2025
  3. STRAIN R, Edmans M, Montalvo Zurbia-Flores G, Frumento N, et al
    The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.
    Hepatology. 2025 Nov 14. doi: 10.1097/HEP.0000000000001599.
    >> Share

    September 2025
  4. SANDULESCU O, Dudman SG, Gmizic I, Garcia F, et al
    Global Hepatitis C elimination: Updates, challenges, and opportunities from real-world experiences in Europe and North America.
    Hepatology. 2025 Sep 26. doi: 10.1097/HEP.0000000000001548.
    >> Share

  5. GOMEZ-ESCOBAR E, Flores N, Shoukry NH
    One step closer to a pan-genotypic hepatitis C vaccine.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001530.
    >> Share

    June 2025
  6. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
    Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2025;81:E181.
    >> Share

    February 2025
  7. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2025;81:609-624.
    >> Share

    January 2025
  8. YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
    Prevalence and predictors of cirrhosis and portal hypertension in the united states.
    Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
    >> Share

  9. PATEL K, Asrani SK, Fiel MI, Levine D, et al
    Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2025;81:358-379.
    >> Share

    November 2024

  10. Erratum: JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralization.
    Hepatology. 2024;80:E86.
    >> Share

    October 2024
  11. COLPITTS CC, Baumert TF
    Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions.
    Hepatology. 2024 Oct 22. doi: 10.1097/HEP.0000000000001132.
    >> Share

  12. OLESEN CH, Collignon L, Velazquez-Moctezuma R, Fanalista M, et al
    Prevalence of hepatitis C virus hypervariable region 1 insertions and their role in antibody evasion.
    Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001114.
    >> Share

    August 2024
  13. VAN DER MEER AJ, Sonneveld MJ
    Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
    >> Share

  14. STAFYLIS C, Vij AP, Klausner JD
    Letter to the editor: Bridging the gap between hepatitis C virus diagnosis and treatment to achieve elimination in the united states.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001051.
    >> Share

    July 2024
  15. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001005.
    >> Share


  16. Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    >> Share

    June 2024
  17. LAW JL, Drummer HE
    Bridging the gap: A new tool to down select HCV vaccine candidates.
    Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000000948.
    >> Share

  18. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
    Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
    >> Share

  19. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    >> Share

  20. CORNBERG M, Wedemeyer H
    Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination!
    Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958.
    >> Share

    May 2024
  21. POL S, Thompson AJ, Collins M, Venier E, et al
    Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
    Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
    >> Share

  22. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
    The obstacle is the way: Finding a path to hepatitis C elimination.
    Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
    >> Share

  23. HALL EW, Bradley H, Barker LK, Lewis K, et al
    Estimating hepatitis C prevalence in the United States, 2017-2020.
    Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
    >> Share

  24. SEMMLER G, Mandorfer M
    The fade-out of HCV coinfection of people who live with HIV.
    Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
    >> Share

    April 2024
  25. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
    JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
    >> Share

    March 2024
  26. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
    >> Share

  27. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    >> Share

  28. KONDILI LA, Craxi A
    Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
    >> Share

    February 2024
  29. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    >> Share

  30. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    >> Share

  31. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    >> Share

    January 2024
  32. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    >> Share

  33. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    >> Share

    November 2023
  34. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    >> Share

    July 2023
  35. MUFTAH AA, Banala C, Raasikh T, Jamali T, et al
    Telehealth interventions in patients with chronic liver diseases: A systematic review.
    Hepatology. 2023;78:179-194.
    >> Share

    June 2023
  36. GOMER A, Klohn M, Jagst M, Nocke M, et al
    Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
    Hepatology. 2023 Jun 20. doi: 10.1097/HEP.0000000000000514.
    >> Share

  37. GOUTTENOIRE J, Neyts J
    Towards antivirals against hepatitis E: In the steps of hepatitis C.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000509.
    >> Share

    May 2023
  38. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
    The national hepatitis c elimination program - AASLD's coalition and call to action.
    Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
    >> Share

    April 2023
  39. DIETZ J, Lohmann V
    Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
    >> Share

  40. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    >> Share

  41. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016